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ABSTRACT Emerging coronaviruses (CoVs) cause severe disease in humans, but no 
approved therapeutics are available. The CoV nsp14 exoribonuclease (ExoN) has 
complicated development of antiviral nucleosides due to its proofreading activity. 
We recently reported that the nucleoside analogue GS-5734 (remdesivir) potently in-
hibits human and zoonotic CoVs in vitro and in a severe acute respiratory syndrome 
coronavirus (SARS-CoV) mouse model. However, studies with GS-5734 have not re-
ported resistance associated with GS-5734, nor do we understand the action of GS-
5734 in wild-type (WT) proofreading CoVs. Here, we show that GS-5734 inhibits mu-
rine hepatitis virus (MHV) with similar 50% effective concentration values (EC50) as
SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV). Passage of WT 
MHV in the presence of the GS-5734 parent nucleoside selected two mutations in the 
nsp12 polymerase at residues conserved across all CoVs that conferred up to 5.6-fold re-
sistance to GS-5734, as determined by EC50. The resistant viruses were unable to com-
pete with WT in direct coinfection passage in the absence of GS-5734. Introduction of 
the MHV resistance mutations into SARS-CoV resulted in the same in vitro resistance 
phenotype and attenuated SARS-CoV pathogenesis in a mouse model. Finally, we dem-
onstrate that an MHV mutant lacking ExoN proofreading was significantly more sensitive 
to GS-5734. Combined, the results indicate that GS-5734 interferes with the nsp12 poly-
merase even in the setting of intact ExoN proofreading activity and that resistance can 
be overcome with increased, nontoxic concentrations of GS-5734, further supporting the 
development of GS-5734 as a broad-spectrum therapeutic to protect against contempo-
rary and emerging CoVs.
IMPORTANCE Coronaviruses (CoVs) cause severe human infections, but there are 
no approved antivirals to treat these infections. Development of nucleoside-based 
therapeutics for CoV infections has been hampered by the presence of a proofread-
ing exoribonuclease. Here, we expand the known efficacy of the nucleotide prodrug 
remdesivir (GS-5734) to include a group -2a CoV. Further, GS-5734 potently inhibits 
CoVs with intact proofreading. Following selection with the GS-5734 parent nucleo-
side, 2 amino acid substitutions in the nsp12 polymerase at residues that are identi-
cal across CoVs provide low-level resistance to GS-5734. The resistance mutations 
decrease viral fitness of MHV in vitro and attenuate pathogenesis in a SARS-CoV ani-
mal model of infection. Together, these studies define the target of GS-5734 activity 
and demonstrate that resistance is difficult to select, only partial, and impairs fitness
Coronaviruses (CoVs) are positive-sense, single-stranded RNA viruses that infect awide range of animal hosts. In humans, CoVs were recognized as typically causing
and virulence of MHV and SARS-CoV, supporting further development of GS-5734 as 
a potential effective pan-CoV antiviral.
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colds and pneumonia until the emergence of severe acute respiratory syndrome 
coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus 
(MERS-CoV) in 2012 from zoonotic sources (1, 2). Although the SARS epidemic was 
controlled by public health measures within a year of its emergence, the virus spread 
to over 30 countries and was associated with a 10% mortality rate (3). Efforts to treat 
SARS patients with existing antivirals did not conclusively provide a clinical benefit and 
may have even worsened disease (4–7). MERS-CoV continues to circulate in the Middle 
East, with a case fatality rate approaching 40% (http://www.who.int/emergencies/mers 
-cov/en/). Currently, there are no FDA-approved antivirals or vaccines for the treatment 
and prevention of MERS-CoV infection. Supportive care and prevention of complica-
tions constitute the current standard of treatment for patients, emphasizing the need 
for direct-acting antivirals (8, 9). Furthermore, SARS- and MERS-like bat CoVs circulate in 
nature, can replicate efficiently in primary human airway cells, and use the same cellular 
receptors for entry as human CoVs (10–13). The imminent threat of human emergence 
underscores the need for broadly active antivirals to combat any CoV that may emerge.
Nucleoside analogues commonly target viral replication, particularly the viral DNA or 
RNA polymerase (14), and have succeeded clinically in treating multiple viral infections 
(15). However, identification and development of antiviral nucleosides against corona-
viruses have been hampered by the presence of the unique CoV proofreading 3=-5= 
exoribonuclease (ExoN) (16–18). While nucleoside analogues such as BCX4430 inhibit 
CoVs (19), several previously tested nucleoside analogues have been incapable of 
potently inhibiting CoV replication, and others have demonstrated poor selectivity 
indexes (20, 21). We have shown that CoV resistance to the mutagens 5-fluorouracil 
(5-FU) and ribavirin (RBV) in vitro is attributed to their removal by the proofreading 
ExoN (22), supporting the hypothesis that an effective nucleoside analogue must evade 
proofreading to successfully interfere with CoV RNA synthesis.
We recently reported that GS-5734, the monophosphoramidate prodrug of the 
C-adenosine nucleoside analogue GS-441524 (Fig. 1A), inhibits SARS-CoV, MERS-CoV, 
and bat CoV strains that are capable of replicating in primary human airway epithelial 
cells and mediate entry using human CoV receptors (23–25). GS-5734 also demon-
strates both prophylactic and therapeutic efficacy against SARS-CoV disease in a mouse 
model (23). However, the study was not designed to define, nor did it report, potential 
pathways and implications of resistance for virus fitness and virulence. Further, studies 
demonstrating the efficacy of GS-5734 against CoVs and other viruses, including 
Ebolavirus, have not described resistance mutations. Using the model -coronavirus 
murine hepatitis virus (MHV), we here demonstrate that GS-5734 dramatically inhibits 
viral replication and viral RNA synthesis in wild-type (WT) virus, while an nsp14 ExoN() 
mutant lacking proofreading demonstrates increased susceptibility to GS-5734. Passage 
of WT MHV with the GS-5734 parent nucleoside GS-441524 resulted in phenotypic 
resistance associated with two nonsynonymous mutations in the predicted fingers 
domain of the nsp12 RNA-dependent RNA polymerase (F476L and V553L). The engi-
neered mutations in the MHV cloned background closely recapitulated the partial 
resistance phenotype and restored RNA levels in the presence of GS-5734. However, 
resistant viruses could not compete with WT MHV during in vitro coinfection passage 
in the absence of GS-5734. Introduction of homologous substitutions in mouse-
adapted SARS-CoV conferred resistance to GS-5734 similar to that seen in MHV but also 
attenuated in vivo pathogenesis of SARS-CoV in a mouse model. Overall, our results are 
consistent with an RNA-dependent RNA polymerase (RdRp)-mediated mechanism of
potent CoV inhibition by GS-5734, even in the setting of intact ExoN-mediated proof-
reading.
RESULTS
FIG 1 GS-441524 and GS-5734 inhibit MHV with minimal cytotoxicity. (A) GS-441524 is a 1=-cyano 4-aza-7,9-dideazaadenosine C-adenosine nucleoside
analogue. (B) Change in viral titer of MHV compared to vehicle control after treatment with GS-441524. The data represent the results from 2 independent
experiments, each with 3 replicates. Error bars represent standard error of the mean (SEM). (C) Viral titer data from panel B presented as the percentage of
uninhibited control. The EC50 of GS-441524 was calculated to be 1.1 M. (D) Cell viability normalized to the vehicle control after treatment with GS-441524.
The data represent the results from 3 independent experiments, each with 3 replicates. Error bars represent SEM. (E) GS-5734 is a monophosphoramidate
prodrug of GS-441524. (F) Change in viral titer of MHV compared to vehicle control after treatment with GS-5734. The data represent the results from 4
independent experiments, each with 3 replicates. Error bars represent SEM. (G) Viral titer data from panel F presented as the percentage of uninhibited control.
The EC50 of GS-5734 was calculated to be 0.03 M. (H) Cell viability normalized to vehicle control after treatment with GS-5734. The data represent the results
from 3 independent experiments, each with 3 replicates. Error bars represent SEM.
GS-441524 and GS-5734 inhibit MHV replication. GS-441524, a 1=-cyano 4-aza-
7,9-dideazaadenosine C-nucleoside (Fig. 1A), has been shown to inhibit multiple virus 
families in vitro (24, 26). To determine if GS-441524 inhibited the model -2a CoV, 
murine hepatitis virus (MHV), we infected delayed brain tumor (DBT) cells with MHV and 
treated them with increasing concentrations of drug. We observed a dose-dependent 
reduction in viral titer with up to a 6-log10 decrease at 11.1 M GS-441524 (Fig. 1B). The 
half-maximum effective concentration (EC50) value resulting from GS-441524 treatment 
was 1.1 M (Fig. 1C). We observed minimal detectable cytotoxicity within the tested 
range, with the concentration resulting in 50% cytotoxicity (CC50) 300 M (Fig. 1D). 
This resulted in a selectivity index (CC50/EC50) of 250. Having demonstrated the 
inhibition of MHV by GS-441524, we next tested its monophosphoramidate prodrug 
GS-5734 (Fig. 1E). Treatment with increasing concentrations of GS-5734 resulted in up 
to a 6-log10 decrease in viral titer, and virus was undetectable by plaque assay at 
concentrations above 0.5 M GS-5734 (Fig. 1F). GS-5734 inhibited MHV more potently
than GS-441524, with a GS-5734 EC50 of 0.03 M (Fig. 1G), consistent with higher
cellular permeability and more efficient metabolism of the prodrug into the active 
nucleoside triphosphate by bypassing the rate-limiting first phosphorylation step (27, 
28). We also observed minimal cytotoxicity at concentrations required for antiviral 
activity of GS-5734, in line with previously reported extensive cytotoxicity studies in 
relevant human cell types (27), with a CC50 value of 39 M (Fig. 1H), resulting in a 
selectivity index of 1,000. These results expand the breadth of GS-441524 and 
GS-5734 inhibition of CoVs to include the -2a model CoV MHV.
GS-441524 and GS-5734 potently inhibit SARS-CoV and MERS-CoV in HAE cells. 
Primary human airway epithelial cell (HAE) cultures are among the most clinically 
relevant in vitro models of the lung, recapitulating the cellular complexity and physi-
ology of the epithelium in the human conducting airway (29). Previous results have
demonstrated that GS-5734 inhibits the viral titer of multiple CoVs in this model, but
did not assess the potency or the effect of delaying treatment with the compound.
Thus, we determined the EC50 values after treatment with GS-441524 and GS-5734 in
SARS-CoV- and MERS-CoV-infected HAE cultures. Mean EC50 values for both viruses
were approximately 0.86 M for GS-441524 and 0.074 M for GS-5734 (Fig. 2A). Further,
delaying addition of GS-5734 until 24 hours (h) postinfection resulted in decreased viral
titer in HAE cultures for both SARS-CoV (Fig. 2B) and MERS-CoV (Fig. 2C) at 48 and 72 h
postinfection. No measurable cellular toxicity was observed in HAE cultures for either
compound (Table 1). These results demonstrate a similar high potency of GS-5734
across divergent CoVs, supporting the utility of the model MHV system to study GS-5734
inhibition and resistance.
GS-5734 acts at early times postinfection to decrease viral RNA levels. The
predicted mechanism of action of GS-5734 is through incorporation of the active
triphosphate into viral RNA (27). We therefore tested the hypothesis that GS-5734
would inhibit CoVs at early steps in replication by inhibiting viral RNA synthesis. To
determine which stage in the viral replication cycle GS-5734 inhibited CoVs, we infected
cells with MHV at a multiplicity of infection (MOI) of 1 PFU/cell, which with MHV results
in a single-cycle infection, and treated them with 2 M GS-5734 at 2-h intervals from
2 h preinfection to 10 h postinfection. We observed maximal inhibition when GS-5734
was added between 2 h preinfection and 2 h postinfection. Less inhibition was
detected when GS-5734 was added between 4 and 6 h postinfection, and no inhibition
was observed when GS-5734 was added after 8 h postinfection (Fig. 3A). These results
demonstrate that GS-5734 inhibits CoVs at early steps during infection. Because viral
RNA is synthesized early in infection and GS-5734 is implicated in inhibiting viral RNA
synthesis (25, 30, 31), we next determined the cellular level of viral RNA by real-time
quantitative PCR (qPCR) after treatment with GS-5734. Treatment with increasing
FIG 2 Antiviral activity of GS-441524 and GS-5734 and modeled therapeutic efficacy of GS-5734 against SARS-CoV and MERS-CoV in HAE cultures. (A) Mean
EC50 values of SARS-CoV and MERS-CoV-infected HAE cultures from three different patient isolates treated with GS-441524 or GS-5734. (B) Viral titers of
SARS-CoV-infected HAE cultures when treated with various doses of GS-5734 24 h postinfection. (C) Viral titers of MERS-CoV-infected HAE cultures when treated
with various doses of GS-5734 24 h postinfection.




EC50 (M) CC50 (M) EC50 (M) CC50 (M)
MERS 0.86  0.78 100 0.074  0.023 10
SARS 0.18  0.14 100 0.069  0.036 10
aValues represent the average (mean  SD) from HAE cultures from at least three donors.
concentrations of GS-5734 resulted in decreased viral RNA levels that correlated with
the decrease in titer we observed (Fig. 3B). These results suggest that GS-5734 inhibits
CoVs early after infection by interfering with viral RNA replication.
Viruses lacking ExoN-mediated proofreading are more sensitive to treatment
with GS-5734. We have shown that the profound resistance of CoVs to the nucleoside
and base analogues RBV and 5-FU is due to the proofreading ExoN in nsp14, as
engineered ExoN() mutant MHV and SARS-CoV are profoundly more sensitive to
these compounds (22). We therefore compared the sensitivity of WT and ExoN() MHV
to GS-5734. ExoN() MHV demonstrated up to a 100-fold greater reduction in viral titer
at 0.25 M GS-5734 compared to WT virus (Fig. 4A), and the calculated EC50 for ExoN()
virus in this experiment was 0.019 M, a 4.5-fold decrease compared to the WT EC50 of
0.087 M (Fig. 4B). This increased sensitivity of ExoN() virus to GS-5734 is similar to
that of other nucleoside analogues and suggests that GS-5734 is incorporated into viral
RNA and can be removed by ExoN. However, the results also suggest there is a
fundamentally different relationship of GS-5734 with the CoV replicase and/or template
RNA compared with other nucleosides such as ribavirin or 5-fluorouracil, since GS-5734
potently inhibits CoVs with intact proofreading (22).
FIG 3 GS-5734 acts at early times postinfection to decrease viral RNA levels. (A) MHV viral titer after
single-cycle infection and treatment with 2 M GS-5734 at the indicated times postinfection. The data
represent the results from 2 independent experiments, each with 3 replicates. Error bars represent SEM.
Statistical significance compared to addition of GS-5734 at 0 h postinfection (p.i.) was determined by
one-way analysis of variance (ANOVA) with Dunnett’s post hoc test for multiple comparisons and is denoted
by asterisks: *, P  0.05; **, P  0.01; ***, P  0.001. (B) Change in viral titer (black bars) and viral RNA levels
(hatched bars) normalized to vehicle control 10 h postinfection after treatment with GS-5734. The data
represent the results from 2 independent experiments, each with 3 replicates. Error bars represent SEM.
Statistical significance compared to DMSO-treated samples was determined by one-way ANOVA with
Dunnett’s post hoc test for multiple comparisons and is denoted by asterisks: **, P  0.01; ***, P  0.001.
FIG 4 Viruses lacking ExoN-mediated proofreading are more sensitive to GS-5734 inhibition. (A) Change in 
viral titer of WT and ExoN() viruses normalized to vehicle control after treatment with GS-5734. The data 
represent the results from 2 independent experiments, each with 3 replicates. Error bars represent SEM. 
Statistical significance compared to WT at each concentration was determined by t test using the 
Holm-Sidak method to correct for multiple comparisons and is denoted by asterisks: ***, P  0.001. (B) Viral 
titer reduction from panel A represented as percentage of vehicle control, resulting in a WT EC50 value of 
0.087  M and an ExoN() EC50 of 0.019 M.
FIG 5 Two mutations in the predicted fingers domain of the nsp12 RdRp, F476L and V553L, arose after 23 passages in the presence of GS-441524, and these
residues are completely conserved across CoVs. (A) Schematic of the MHV genome displaying proteins with mutations identified after passage with GS-441524.
The nsp12 RdRp is shown in yellow, nsp13-helicase in purple, ns2 in green, and spike in blue. (B) Linear schematic of nsp12 showing the locations of F476L
and V553L within the predicted fingers of the RdRp core domain. (C) The previously described (32) Phyre2 model of the MHV RdRp core domain was used to
map the predicted locations of the F476L and V553L residues, shown here in orange. The SDD active site residues are shown in yellow, the palm in red, the
fingers in blue, and the thumb in green. (D) Amino acid conservation of F476 and V553 residues across CoVs demonstrating that both of these residues are
completely conserved.
Two mutations in the RdRp mediate partial resistance and restoration of RNA 
levels in the presence of GS-5734. We next sought to identify the target(s) of GS-5734 
inhibition. Three lineages of WT MHV were serially passaged in the presence of 
increasing concentrations of GS-441524. GS-441524 was chosen for passage selection 
because GS-5734 and GS-441524 are both metabolized to the same active triphosphate 
metabolite (27), but GS-441524 provided a larger working range of concentrations. Two 
lineages did not demonstrate an increase in viral cytopathic effect (CPE) over passage 
and were lost after passages 17 (p17) and p20. After 23 passages, we observed an 
increased ability of one passage lineage to replicate in the presence of GS-441524 as 
determined by increased viral CPE. Full-genome sequencing of p23 viral RNA revealed 
6 nonsynonymous mutations in four viral protein-coding regions (Fig. 5A): the nsp13 
helicase (A335V), the ns2 2=,5= phosphodiesterase (Q67H), the spike glycoprotein (A34V 
and I924T), and the nsp12 RdRp (F476L and V553L) (Fig. 5B). Molecular modeling of the 
MHV RdRp predicts that both the F476 and V553 residues reside within the predicted 
fingers domain of the conserved right-hand structure of the RdRp (Fig. 5C) (32, 33). In 
addition, both the F476 and V553 residues are identical across sequenced -, -, and 
-CoVs (Fig. 5D). Based on the known role of polymerase mutations in resistance to 
nucleoside analogues for other viruses (34–37) and the previous work describing 
inhibition of the respiratory syncytial virus (RSV) polymerase by GS-5734 (27), we first 
engineered and recovered recombinant MHV containing the F476L and V553L RdRp 
mutations to determine if they were necessary and sufficient for the observed resis-
tance phenotype of the p23 virus population. Recombinant MHV containing either 
F476L or V553L individually was less sensitive to GS-5734 than WT MHV, but still more 
sensitive than the p23 virus population across a broad range of concentrations. In 
contrast, MHV encoding both F476L and V553L demonstrated a resistance pattern 
comparable to p23 (Fig. 6A). Neither the p23 virus population nor any of the recom-
binant viruses were completely resistant to GS-5734; all viruses remained sensitive to 
higher but nontoxic concentrations of GS-5734. Compared to WT MHV, the F476L virus
showed 2.4-fold resistance to GS-5734, and V553L virus demonstrated 5-fold resistance
to GS-5734, while combined mutations mediated 5.6-fold resistance to GS-5734 based
on EC50 values (Table 2). Because GS-5734 decreases viral RNA levels, we next tested if
resistance mutations restored RNA synthesis. We observed that RdRp resistance muta-
tions partially restored RNA levels in the presence of GS-5734 and that the degree of
FIG 6 The F476L and V553L mutations mediate resistance to GS-5734 and are associated with a fitness defect. (A) Change in
viral titer of WT, F476L, V553L, F476L  V553L, and p23 viruses normalized to the vehicle control after treatment with GS-5734.
The data represent 2 independent experiments, each with 3 replicates. Error bars represent SEM. Statistical significance
compared to WT was determined by Kolmogorov-Smirnov test and is denoted by asterisks: *, P  0.05. (B) The change in
genomic RNA levels of WT, F476L, V553L, and F476L  V553L MHV normalized to vehicle control after treatment with GS-5734.
The data represent the results from 2 independent experiments, each with 3 replicates. Error bars represent SEM. Statistical
significance compared to WT at each concentration was determined by one-way ANOVA with Dunnett’s post hoc test for
multiple comparisons and is denoted by asterisks: *, P  0.05; **, P  0.01. (C) Multi-cycle replication kinetics of WT, F476L,
V553L, or F476L  V553L MHV. The data represent the results from 2 independent experiments, each with 3 replicates. Error
bars represent SEM. (D) Coinfection competition assay of WT and F476L V553L MHV at the indicated ratios. The percentage
of the population of each mutation was assessed after four successive passages. The data are representative of 2 independent
experiments each with 2 replicates. Error bars represent standard deviation (SD).
TABLE 2 F476L and V553L mutations confer up to 5.6-fold resistance to GS-5734 in
MHVa
Virus EC50 (M) Fold resistance
WT 0.024  0.011 1
F476L 0.057  0.040 2.4
V553L 0.12  0.06 5.0
F476L  V553L 0.13  0.06 5.6
aMean EC50 values  SD and fold resistance of GS-5734-resistant viruses were calculated using viral titer
data following infection of DBT cells with the indicated virus at an MOI of 0.01 PFU/cell and treatment with
increasing concentrations of GS-5734. Fold resistance was calculated as EC50 of mutant/EC50 of WT. The 
data represent the results from 3 independent experiments, each with 3 replicates.
restoration of RNA levels correlated with their fold resistance to GS-5734 (Fig. 6B). 
Together, these results are consistent with a mechanism of action of GS-5734 primarily 
targeting RdRp-mediated RNA synthesis.
GS-5734 resistance mutations impair competitive fitness of MHV. To assess the 
effect of GS-5734 resistance on viral fitness, we first determined the replication capacity 
of recombinant MHV carrying the F476L, V553L, and F476L  V553L mutations. Each of 
these viruses replicated similarly to WT MHV, both in replication kinetics and in 
observed peak titer (Fig. 6C). We next tested the competitive fitness of F476L  V553L 
MHV compared to WT MHV during coinfection over multiple passages. Murine DBT cells 
were coinfected with WT MHV and F476L  V553L MHV at WT/mutant ratios of 1:1, 1:9, 
or 9:1 in the absence of GS-5734, and infected culture supernatants were serially 
passaged 3 times to fresh cell monolayers. By passage 2, F476L  V553L MHV was 
outcompeted by WT MHV in the population at every input ratio (Fig. 6D), demonstrat-
ing a competitive fitness cost of the F476L  V553L mutations in the absence of 
GS-5734. This competitive fitness cost further suggests that GS-5734 resistance muta-
tions will not persist in the absence of treatment.
Mutations identified in GS-5734-resistant MHV also confer resistance in SARS-
CoV. Given the complete conservation of the F476 and V553 residues across CoVs, we 
next tested whether substitutions at the homologous SARS-CoV residues (F480L and 
V557L) could confer resistance to GS-5734. We recovered SARS-CoV carrying the 
homologous F480L and V557L substitutions and tested recovered mutant viruses for 
resistance to GS-5734 in Calu-3 2B4 cells. WT SARS-CoV demonstrated dose-dependent 
inhibition by GS-5734, with an EC50 of 0.01 M (Fig. 7A). The F480L  V557L recom-
binant virus was inhibited by GS-5734, with an EC50value of 0.06 M, representing a
6-fold resistance to GS-5734 (Fig. 7B), nearly identical to the fold resistance of F476L  
V553L MHV. These results support the conclusion that the conserved residues across 
divergent CoVs reflect conserved functions impaired by GS-5734, potentially implying 
common pathways to resistance across CoVs.
GS-5734-resistant SARS-CoV is attenuated in vivo. To gain insight into the patho-
genic potential of GS-5734-resistant viruses, we directly compared WT SARS-CoV and 
F480L V557L SARS-CoV following non-lethal high-dose (104 PFU) and low-dose 
(103 PFU) inoculation in a well-characterized mouse model of SARS-CoV pathogenesis 
with disease reminiscent of that observed in humans (38). Mice infected with a high 
dose of F480L V557L SARS-CoV lost significantly less weight (P  0.05) than WT 
SARS-CoV-infected mice (Fig. 7C). At 2 days postinfection, mouse lung viral titers were 
similar between WT and F480L  V557L SARS-CoV, but by 4 days postinfection, lung 
viral titers were significantly reduced (P  0.05) in mice infected with F480L  V557L 
SARS-CoV (Fig. 7D). Together, these data demonstrate that GS-5734-resistant SARS-CoV 
is attenuated in its ability to cause disease and replicates less efficiently than WT virus 
in robust mouse models of human SARS-CoV disease.
DISCUSSION
Broadly active antivirals are needed to treat contemporary human CoV infections, 
including endemic MERS-CoV in the Middle East and potential future zoonotic CoV 
epidemics. We recently demonstrated the prophylactic and therapeutic efficacy of 
GS-5734 (remdesivir) in a mouse model of SARS-CoV infection, as well as in vitro activity 
against multiple other human and zoonotic CoVs (23). In this study, we have defined 
the ability of GS-5734 to inhibit CoVs— expanded to include group 2a -CoVs—in the 
setting of intact nsp14 proofreading activities. While ExoN() MHV is 4.5-fold more 
sensitive to GS-5734 treatment than WT MHV, the potent inhibition of WT CoVs 
suggests a unique mechanism of inhibition of CoV RNA synthesis that is able to 
circumvent ExoN surveillance and activity. Further, we report for the first time for any 
virus inhibited by GS-5734 that selection for partial resistance to GS-5734 required 
prolonged passage. Surprisingly, no resistance mutations were selected within ExoN, 
but rather two mutations of highly conserved residues in the RdRp reduced the 
sensitivity to GS-5734 to a level comparable to that of the passaged virus. Introduction
FIG 7 MHV resistance mutations confer resistance and are attenuated in SARS-CoV. (A) Change in luciferase activity
normalized to vehicle control of WT or F480L  V557L SARS-CoV containing the NanoLUC reporter. The data are
representative of the results from 2 independent experiments, each with 3 replicates. Error bars represent SEM. (B)
Viral titer data from panel A presented as the percentage of vehicle control. This EC50 value was calculated as
0.01 M for WT and 0.06 M for F480L  V557L virus, which represents a 6-fold increase in resistance. (C) Percent
starting weight of BALB/c mice inoculated with WT or F480L  V557L SARS-CoV containing the NanoLUC reporter
at 103 or 104 PFU. The data are representative of the results from 2 independent experiments, each with 10 to 12
animals per group. Error bars represent SEM. Statistical significance was determined by 2-way ANOVA and is
denoted by asterisks: *, P  0.05. (D) Lung titers from animals in panel C 2, 4, and 7 days postinfection. The data
are representative of the results from 2 independent experiments, each with 3 animals per group. Error bars
represent SEM. Statistical significance was determined by Wilcoxon test and is denoted by asterisks: *, P  0.05.
of the homologous substitutions in SARS-CoV reproduced the fold resistance to GS-
5734 observed in MHV, demonstrating the potential for common, family-wide drug 
resistance pathways in the RdRp.
Potential GS-5734 mechanism of action. Nucleoside analogues can have multiple 
mechanisms of action, including lethal mutagenesis, obligate or nonobligate chain 
termination, and perturbation of natural nucleotide triphosphate pools via inhibition of 
nucleotide biosynthesis (14, 39–44). GS-5734 has been reported to cause premature 
termination of nascent RNA transcripts by the purified RSV polymerase, but the 
mechanism of inhibition of other viral polymerases has not been fully explored (27). Our 
data demonstrate that GS-5734 acts early in infection and decreases RNA levels in a 
dose-dependent manner that parallels impairment of viral titer. Further, while GS-5734 
is highly active against WT CoVs, it is 4.5-fold more active in MHV lacking the proof-
reading activity of ExoN. Finally, GS-5734 is 3 to 30 times more active than GS-441524 
in all of the CoVs we have tested (23). The result is consistent with the report that 
GS-5734 is metabolized more efficiently than GS-441524 into the triphosphate metab-
olite (27). All of the above findings support a mechanism involving incorporation of 
GS-5734 into nascent CoV RNA, but do not discriminate between chain termination and 
incorporation mutagenesis. In fact, other nucleoside analogues have multiple proposed 
mechanisms of virus inhibition, including favipiravir in influenza virus and RBV in HCV 
(41–43). Future studies using deep sequencing and biochemical approaches will allow 
us to precisely define the GS-5734 mechanism(s) of action against CoVs.
Nucleoside analogues have been approved to treat a variety of RNA and DNA 
viruses, but CoVs have been refractory to inhibition by some nucleoside analogues (22). 
This resistance to potent inhibition by RBV and 5-FU has been attributed to the CoV 
nsp14 proofreading exoribonuclease. We have previously reported that MHV and 
SARS-CoV strains lacking the proofreading activity of ExoN [ExoN()] were more 
sensitive to 5-FU and RBV, underscoring the role of ExoN-mediated proofreading in 
resistance to inhibition by these compounds (22). These results suggest that to effec-
tively inhibit CoVs, nucleoside analogues would need to inhibit ExoN directly, be 
incorporated so efficiently that the 5=-3= elongation reaction is much faster than the 
ExoN cleavage reaction, or not be recognized for ExoN-mediated removal. The latter 
mechanism has been proposed for sensitivity of herpes simplex virus (HSV) to acyclovir; 
specifically, that the HSV exonuclease is unable to remove acyclovir (45). Here, we show 
that ExoN() MHV is more sensitive than WT MHV to GS-5734 treatment. This result 
suggests that GS-5734 is recognized, at least partially, by a functional ExoN, but that the 
ExoN activity is not sufficient to prevent potent inhibition of CoV replication. One 
possible explanation is that GS-5734 may be recognized and removed by ExoN less 
efficiently than these mutagens or other incorrect nucleotides, though further studies 
are needed to fully understand the role of ExoN in GS-5734 inhibition of CoVs. Overall, 
the enhanced activity of the monophosphate prodrug, the increased sensitivity of 
ExoN() viruses to GS-5734 inhibition, selected resistance mutations in the modeled 
RdRp finger domain, the time-dependent viral inhibition profile, and decreased viral 
RNA levels support the hypothesis that GS-5734 directly inhibits viral RNA synthesis.
Mechanism of resistance to GS-5734. Previous studies have assessed inhibition by 
GS-5734 in multiple viruses, but none have reported resistance mutations during 
treatment. In this study, passage of MHV in the presence of GS-441524 resulted in 
selection of 5.6-fold resistance. Sequencing identified consensus nonsynonymous 
F476L and V553L mutations in the nsp12 core polymerase-coding region. A similar level 
of resistance was observed for the homologous F480L and V557L substitutions in 
SARS-CoV. As these mutations are not in the immediate vicinity of the RdRp active site, 
the mechanism of resistance to GS-5734 remains to be determined. Both of these 
residues are conserved across CoVs, suggesting that they mediate conserved functions. 
Sequence alignment and molecular modeling of the CoV RdRp predicts that V553L lies 
within motif F of the fingers domain, which forms a channel for incoming NTPs and 
contacts the 5=end of the template, while F476L is not within any defined structural 
motif but also resides in the fingers domain (33, 46). Resistance mutations to nucleoside 
analogues, including those that lie in the fingers domain, have been implicated in 
altering replication fidelity as a mechanism of resistance in picornaviruses and HIV (34, 
47, 48). In a previous study, using homology modeling of the CoV RdRp based on the 
coxsackievirus B3 RdRp structure, we predicted and confirmed that a V553I substitution 
in the MHV RdRp increases CoV fidelity in ExoN() viruses (32), suggesting that viral 
replication fidelity modulation may also impact susceptibility to GS-5734. This is 
supported by the result that GS-5734, while highly active in WT virus, is even more 
potent in the absence of nsp14 ExoN proofreading activity. However, the CoV replicase 
encodes many proteins, and these mutations may alter protein-protein interactions 
among these components. The availability of an in vitro biochemical system demon-
strating both polymerase and exoribonuclease activities suggests it may be possible to 
define specific effects of GS-5734 resistance mutations on polymerase and RNA proof-
reading activities (49, 50). Thus, it will be interesting to determine if F476L and V553L 
confer class-level resistance to nucleotide analogues, general increased fidelity, 
changes in specific nucleotide selectivity, alterations in replicase-protein interactions, or 
other novel mechanisms.
Recombinant MHV containing the F476L and V553L mutations very closely recapit-
ulated the GS-5734 resistance phenotype of passage 23 virus population, confirming 
the importance of these mutations for resistance. However, these results do not 
eliminate the possibility that other potential pathways to GS-5734 resistance may exist.
Additionally, we also identified additional non-RdRp mutations in the consensus se-
quence of passage 23 virus, including another component of the MHV replicase, the 
nsp13 helicase. It will be important to determine if other proteins contribute to 
resistance, as well as using GS-5734 as a probe to define protein interactions and 
functions within the viral replicase.
GS-5734 resistance is associated with a fitness cost in vitro and attenuation in 
vivo. Identification of resistance mutations to antiviral compound candidates in vitro
provides an opportunity to assess the concern that resistance may promote viral fitness, 
leading to enhanced transmission or greater disease severity. The resistance of MHV to 
GS-5734 was very slow to emerge and only partial, suggesting a high genetic barrier to 
resistance, similar to that seen for HCV resistance to the nucleotide antiviral sofosbuvir
(51). Moreover, although recombinant MHV containing both F476L and V553L repli-
cated similarly to WT in parallel cultures, resistant virus failed to compete with WT MHV 
during coinfection over multiple passages, demonstrating a fitness cost associated with 
the resistance mutations that may limit emergence during treatment. The fitness 
impairment was further evidenced in vivo by attenuation of F480L  V557L virus in a 
SARS-CoV mouse model, similar to that reported for other viruses with selected
resistance to nucleotide analogues, including HIV and chikungunya virus (36, 52, 53).
This fitness impairment may be due to alterations in RNA replication, fidelity, nucleotide 
incorporation, or protein stability but suggests that GS-5734 resistance will not lead to 
more transmissible or pathogenic virus.
In summary, our work provides evidence that GS-5734 is highly active against CoVs 
and that there is a high genetic barrier to achieve resistance. Additionally, resistant virus 
suffers a loss of competitive fitness in vitro and attenuation in animals, suggesting these 
mutations will not favor disease emergence and are likely to be poorly maintained in 
nature, particularly during acute infections. Finally, the results identify potential novel 
determinants of polymerase function and nucleotide selectivity or fidelity that will 
guide future structure-function and biochemical studies of the polymerase and GS-
5734 mechanism. Together, these results argue strongly for the continued clinical 
development of GS-5734 to treat MERS-CoV and demonstrate its potential utility in the 
broad-spectrum treatment of CoV infections.
MATERIALS AND METHODS
Cell culture. Murine astrocytoma delayed brain tumor (DBT) cells and baby hamster kidney 21 cells 
expressing the MHV receptor (BHK-R) (54) were maintained at 37°C in Dulbecco’s modified Eagle medium 
(DMEM; Gibco) containing 10% fetal bovine serum (FBS; Invitrogen), penicillin and streptomycin (Gibco), 
HEPES (Gibco), and amphotericin B (Corning). BHK-R cells were further supplemented with 0.8 mg/ml of 
G418 (Mediatech). The human lung epithelial cell line Calu-3 (clone 2B4) was kindly donated by C. T. 
Tseng (University of Texas Medical Branch) (55) and maintained in DMEM (Gibco), 20% fetal bovine serum 
(HyClone), and 1 Gibco antibiotic-antimycotic solution. Human tracheobronchial epithelial cells were 
obtained from airway specimens resected from patients undergoing surgery under University of North 
Carolina Institutional Review Board-approved protocols by the Cystic Fibrosis Center Tissue Culture Core 
(UNC Tissue Core). Primary cells were expanded to generate passage 1 cells, and passage 2 cells were 
plated at a density of 250,000 cells per well on Transwell-COL (12-mm-diameter) supports. Human airway 
epithelium cultures were generated by provision of an air-liquid interface (ALI) for 6 to 8 weeks to form 
well-differentiated, polarized cultures that resembled in vivo pseudostratified mucociliary epithelium (29, 
56, 57).
Viruses. All work with MHV was performed using the recombinant WT strain MHV-A59 (GenBank 
accession no. AY910861) (54). SARS-CoV expressing green fluorescent protein (SARS-GFP) and MERS-CoV 
expressing red fluorescent protein (MERS-RFP) were created from molecular cDNA clones according to 
protocols described previously (29, 57).
Compounds and cell viability studies. GS-441524 and GS-5734 were synthesized at Gilead Sciences, 
Inc., and prepared as 50 and 20 mM stock solutions in dimethyl sulfoxide (DMSO), respectively. Cell 
viability was assessed using CellTiter-Glo (Promega) in 96-well plates according to the manufacturer’s 
instructions. DBT cells were incubated with indicated concentration of compound at 37°C for 24 h. Cell 
viability was determined using a Veritas microplate luminometer (Promega) with values normalized to 
those of untreated cells.
GS-5734 sensitivity studies and generation of EC50 curves. To test MHV sensitivity to GS-441524 
and GS-5734, subconfluent monolayers of DBT cells were infected with the indicated virus at a 
multiplicity of infection (MOI) of 0.01 PFU per cell for 1 h at 37°C. The inoculum was removed and 
replaced with medium containing the indicated concentrations of GS-441524 or GS-5734. Cell superna-
tants were harvested 24 h postinfection. Titers were determined by plaque assay (17). To test the GS-5734
resistance capacity of the F480L  V557L SARS-CoV, Calu-3 2B4 cells were seeded in 96-well plates at a 
density of 5  105 cells/well 48 h prior to infection. The medium was replaced with fresh medium 24 h 
prior to infection to encourage optimal cell growth. Cells were then infected with SARS-CoV F480L  
V557L-NanoLuc or SARS-CoV-WT-NanoLuc at an MOI of ~5 PFU/cell in the presence or absence of 
GS-5734 at 1:3 dilutions, with DMSO (diluent) as an untreated control and UV-inactivated virus as a 
nanoluciferase reporter (NanoLuc) background control. Cells were lysed after incubation at 37°C for 72 h 
using a Promega NanoGlo assay kit and assayed on a luminescence plate reader (SpectraMax M3; 
Molecular Devices). EC50 values and curves were generated with the nonlinear regression curve fit in 
GraphPad Prism software (La Jolla, CA).
In vitro efficacy in human airway epithelial cells. Fully mature HAE cultures were obtained from 
the UNC Tissue Core. At 48 h prior to infection the apical surface of the culture was washed with 500 l 
1 phosphate-buffered saline (PBS) for 1.5 h at 37°C, and the cultures were moved into wells containing 
fresh air-liquid interface (ALI) medium (56). Immediately prior to infection, 500 l of PBS was added to 
the apical surface of the HAE cultures for 30 min at 37°C, the first wash was removed, and a second wash 
was added prior to moving the HAE cultures into ALI medium containing GS-5734 concentrations 
ranging from 0.0016 to 10 M, as indicated for each experiment. The second wash was removed, and 
200 l of viral inoculum (MOI of 0.5 PFU/cell for MERS-RFP and SARS-GFP) was added to the apical surface 
of the cultures for 3 h at 37°C. The viral inoculum was then removed, and the apical surface of the 
cultures was washed three times with 500 l 1 PBS, the final wash was removed, and the cultures were 
incubated at 37°C for a total of 48 h postinfection. For all cultures, apical washes were performed (100 l 
1 PBS) to assess viral replication titers, and then total RNA was collected in 500 l TRIzol (Life 
Technologies/ThermoFisher) and frozen at 80°C prior to extraction for real-time PCR analysis. The data 
that are shown are representative of duplicate sample sets performed with a minimum of three different 
patient isolates. For the therapeutic HAE experiments, cultures were washed as described above, and 
HAE cells remained in drug-free ALI medium for the first day of infection. At 24 h postinfection, cultures 
were moved to ALI medium containing GS-5734 concentrations ranging from 1 to 10 M as indicated. 
Cultures were harvested at 48 h post-drug treatment, which was 72 h postinfection.
Time-of-addition assay. Subconfluent monolayers of DBT cells were infected with WT MHV at an 
MOI of 1 PFU/cell for 1 h at  37°C. The virus inoculum was removed, and fresh medium containing DMSO 
or 2 M GS-5734 was added at the indicated time postinfection. Supernatant was harvested 12 h 
postinfection, and the viral titer was determined by plaque assay.
Real-time qPCR of viral genomic RNA. Subconfluent DBT cells were infected with the indicated 
virus at an MOI of 1 PFU/cell (Fig. 3B) or 0.01 PFU/cell (Fig. 6B). The inoculum was removed after 1 h of  
incubation at 37°C, and medium containing the indicated concentrations of GS-5734 was added. 
Supernatant was collected, and total RNA was harvested using the TRIzol reagent (Invitrogen) after 10 or 
20 h, respectively. The viral titer was determined by plaque assay, and RNA was reverse transcribed using 
SuperScript III (Invitrogen) to generate cDNA that was quantified by quantitative PCR (qPCR) as previ-
ously described (22).
Selection of GS-5734 resistance mutations. WT MHV was passaged in triplicate in increasing 
concentrations of GS-441524, ranging from 1 to 12 M. Infection was initiated for passage 1 at an MOI 
of 0.1 PFU/cell. Supernatant was harvested and frozen when the cell monolayer demonstrated 80%
cytopathic effect (CPE) or after 24 h. A constant volume of 16 l was used to initiate subsequent 
passages. All lineages were maintained until passage 17 (p17). Lineages 2 and 3 were lost after p17 and 
p20, respectively, when virus CPE did not reach above 50% upon multiple efforts and at various 
concentrations of GS-441524. Lineage 1 demonstrated an increase in visible CPE, and thus lineage 1 was 
carried to passage 23. After each passage, total RNA was harvested from infected cell monolayers using 
the TRIzol reagent to be used for viral population sequencing. After passage 23, RNA was extracted and 
reverse transcribed using SuperScript III, followed by generation of amplicons for all three lineages 
covering nsp12 and nsp14 at passage 16 and 12 PCR amplicons to cover the whole genome after 23 
passages of lineage 1. Dideoxy amplicon sequencing was performed by GenHunter (Nashville, TN) and 
analyzed to identify mutations using MacVector.
Modeling and conservation of resistance mutations in the CoV MHV nsp12 RdRp. The F476 and 
V553 residues were located on the previously described MHV RdRp model (32) using the Pymol 
Molecular Graphics System (Schrödinger, LLC). Multiple sequence alignments were generated using 
MacVector.
Cloning, recovery, and verification of mutant viruses. QuikChange mutagenesis was performed 
according to the manufacturer’s protocol to generate mutations in MHV individual genome cDNA 
fragment plasmids using the previously described infectious clone reverse-genetics system (54). Mu-
tants were recovered in BHK-R cells following electroporation of in vitro-transcribed genomic RNA. All 
fragments containing mutations as well as virus stocks were sequenced to ensure mutations were 
present before use in further studies (GenHunter). To generate SARS-CoV encoding nsp12 resistance 
substitutions, a 1,450-bp cassette encoding the substitutions (F480L and V557L) was synthesized by 
BioBasic, Inc. The synthesized cassette was then cloned into the SARS-CoV D infectious cDNA plasmid at 
unique MluI and MstI sites, and the subsequent selected clone was sequence verified across the cassette. 
SARS-CoV expressing the resistance substitutions along with the NanoLuc reporter in place of ORF7 was 
produced as described previously (58).
Virus replication assays. Subconfluent monolayers of DBT cells were infected with WT, F476L, 
V553L, or F476L V553L viruses at an MOI of 0.01 PFU/cell for 1 h. Inocula were removed, and cells were 
washed with PBS before addition of prewarmed medium. Supernatants were harvested at indicated 
times postinfection, and titers were determined by plaque assay.
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